Course: Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
CME Credits: 1.00
Released: 2021-09-02
Two COVID-19 mRNA vaccines, BNT162b2 (ie, Pfizer/BioNTech) and mRNA-1273 (ie, Moderna), were approved via the US Food and Drug Administration Emergency Use Authorization (FDA-EUA) for adults in December 2020. Both incorporate mRNA that encodes for the prefusion stabilized spike glycoprotein, use a prime-boost strategy, and have shown strong immunogenicity in preclinical and clinical studies., Although the 2 vaccines share similar features and both showed strong efficacy in clinical trials, there are formulation differences, and there has been little head-to-head evaluation of antibody responses. In this cohort study, we used a quantitative assay for IgG to SARS-CoV-2 spike-receptor binding protein to compare antibody responses in an employee cohort in which both BNT162b2 and mRNA-1273 were administered. We hypothesized that there could be differences in antibody levels elicited by the 2 vaccines and explored the effect of age on immunogenicity.
Educational Objective
To identify the key insights or developments described in this article
View Full Course